CytoSorbents Corporation · NASDAQ:CTSO

CytoSorbents — Fact Sheet (2023)

4 slides from CytoSorbents's fact sheet, 2023

  1. Slide 1: Organ Perfusion

    Organ Perfusion First CE certified product for cytokine removal in ex-vivo organ perfusion

  2. Slide 2: Organ transplant trends

    Organ transplant trends Increasing number of needed organs – decreasing quality of available organs Globally, more than 125,000 organs are transplanted every year. While a transplantation is often the last resort for the patient, organ availability and access remain a problem. An increased life expe

  3. Slide 3: Introducing ECOS-300CY cytokine adsorption

    Introducing ECOS-300CY® cytokine adsorption Versatile application in different organs, procedures and platforms The new ECOS-300CY® Therapy is an integrated adsorption system for the dialysis of organ perfusion solutions. It has demonstrated the reliable removal of inflammatory mediators like IL-6,

  4. Slide 4: Contact us today to learn more about the new ECOS-300CY Therapy

    Demonstrated removal of inflammatory mediators: IL-6, IL-8, TNF-alpha… Preclinical data proves the efficacy in Steen and Belzer solutions First CE certified product for cytokine removal in ex-vivo organ perfusion Contact us today to learn more about the new ECOS-300CY® Therapy support@cytosorbents.c

CytoSorbents — Fact Sheet (2023) on 6ix